MX2021014575A - Derivados heterociclicos condensados. - Google Patents

Derivados heterociclicos condensados.

Info

Publication number
MX2021014575A
MX2021014575A MX2021014575A MX2021014575A MX2021014575A MX 2021014575 A MX2021014575 A MX 2021014575A MX 2021014575 A MX2021014575 A MX 2021014575A MX 2021014575 A MX2021014575 A MX 2021014575A MX 2021014575 A MX2021014575 A MX 2021014575A
Authority
MX
Mexico
Prior art keywords
condensed heterocyclic
heterocyclic derivatives
compounds
preparing
treatment
Prior art date
Application number
MX2021014575A
Other languages
English (en)
Spanish (es)
Inventor
Zhanling Cheng
Bart Rudolf Romanie Kesteleyn
Tim Hugo Maria Jonckers
Pierre Jean- Marie Bernard RABOISSON
Grosse Sandrine Céline
Yimin Jiang
Serge Maria Aloysius Pieters
Koen Vandyck
Wim Gaston Verschueren
Lili Hu
Scott D Kuduk
Yanping Xu
Gang Deng
Jan Martin Berke
Lamenca Carolina Martinez
Lindsey Graham Deratt
Morgan Charles R Lecomte
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021014575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2021014575A publication Critical patent/MX2021014575A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021014575A 2019-05-28 2020-05-27 Derivados heterociclicos condensados. MX2021014575A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933 2019-05-28
CN2020085720 2020-04-20
PCT/US2020/034643 WO2020243135A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Publications (1)

Publication Number Publication Date
MX2021014575A true MX2021014575A (es) 2022-05-24

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014575A MX2021014575A (es) 2019-05-28 2020-05-27 Derivados heterociclicos condensados.

Country Status (19)

Country Link
EP (1) EP3976617B1 (https=)
JP (1) JP2022535734A (https=)
KR (1) KR20220012913A (https=)
CN (1) CN113906028A (https=)
AU (1) AU2020285718A1 (https=)
BR (1) BR112021022889A8 (https=)
CA (1) CA3138168A1 (https=)
CL (1) CL2021003155A1 (https=)
CO (1) CO2021016433A2 (https=)
CR (1) CR20210666A (https=)
DO (1) DOP2021000230A (https=)
IL (1) IL288322A (https=)
JO (1) JOP20210313A1 (https=)
MA (1) MA56043A (https=)
MX (1) MX2021014575A (https=)
PE (1) PE20220767A1 (https=)
PH (1) PH12021552974A1 (https=)
SG (1) SG11202113167QA (https=)
WO (1) WO2020243135A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744927A (zh) * 2020-12-02 2023-09-12 杨森科学爱尔兰无限公司 稠合杂环衍生物及其在治疗hbv感染中的用途
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
WO2022253255A1 (en) * 2021-06-02 2022-12-08 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives
CN117715909A (zh) 2021-06-02 2024-03-15 杨森科学爱尔兰无限公司 稠合杂环衍生物
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
RU2742305C2 (ru) * 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
AU2017290755B2 (en) * 2016-06-29 2021-07-01 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis B infections
JP6935434B2 (ja) * 2016-06-29 2021-09-15 ノヴィラ・セラピューティクス・インコーポレイテッド オキサジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用
SG11202111236UA (en) * 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)

Also Published As

Publication number Publication date
WO2020243135A1 (en) 2020-12-03
EP3976617B1 (en) 2025-04-23
BR112021022889A2 (pt) 2022-01-04
PE20220767A1 (es) 2022-05-16
CR20210666A (es) 2022-03-11
PH12021552974A1 (en) 2022-07-11
DOP2021000230A (es) 2022-05-31
EP3976617A1 (en) 2022-04-06
CA3138168A1 (en) 2020-12-03
CO2021016433A2 (es) 2021-12-10
BR112021022889A8 (pt) 2024-03-05
CL2021003155A1 (es) 2022-07-22
JP2022535734A (ja) 2022-08-10
MA56043A (fr) 2022-04-06
CN113906028A (zh) 2022-01-07
JOP20210313A1 (ar) 2021-11-25
SG11202113167QA (en) 2021-12-30
AU2020285718A1 (en) 2022-02-03
IL288322A (en) 2022-01-01
KR20220012913A (ko) 2022-02-04

Similar Documents

Publication Publication Date Title
CO2021016433A2 (es) Derivados heterocíclicos condensados
DOP2019000117A (es) Nuevos derivados de quinolina
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37831A (es) Nuevos derivados de quinolina
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX389697B (es) Nuevos derivados de pirazolopirimidina.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2020002891A1 (es) Nuevos derivados de quinolina
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MX2019013878A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
CL2012001579A1 (es) Compuestos derivados de (heterociclo-piperidina condensada)-(piperazinil) 1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1 alcanona, inhibidores de p75; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades neurodegenerativas, esquizofrenia, entre otras; compuesto intermediario.
UY39793A (es) Derivados heterocíclicos condensados
UY39550A (es) Derivados heterocíclicos condensados
ECSP21092791A (es) Derivados heterocíclicos condensados
UY39794A (es) Derivados heterocíclicos condensados
MX2021014581A (es) Derivados heterociclicos condensados.
MX2021014576A (es) Derivados heterociclicos condensados como agentes antivirales.